SUNWAY BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.5 TWD | -0.44% |
|
-0.87% | -15.61% |
| 2023 | SunWay Biotech Co., LTD. agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD.. | CI |
| 2023 | SunWay Biotech Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 380M 11.71M 978M | Sales 2022 | 350M 10.79M 900M | Capitalization | 1.6B 49.2M 4.11B |
|---|---|---|---|---|---|
| Net income 2021 | 169M 5.2M 434M | Net income 2022 | 135M 4.16M 347M | EV / Sales 2021 | 4.46 x |
| Net cash position 2021 | 344M 10.59M 884M | Net cash position 2022 | 87.08M 2.68M 224M | EV / Sales 2022 | 4.31 x |
| P/E ratio 2021 |
12.3
x | P/E ratio 2022 |
12
x | Employees | - |
| Yield 2021 |
7.06% | Yield 2022 |
6.8% | Free-Float | 48.07% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.44% | ||
| 1 week | -0.87% | ||
| Current month | -7.35% | ||
| 1 month | -7.35% | ||
| 3 months | -5.42% | ||
| 6 months | +27.24% | ||
| Current year | -15.61% |
1 week
112.50
120.00
1 month
111.50132.50
Current year
110.00142.50
1 year
47.30145.50
3 years
46.00145.50
5 years
46.00145.50
10 years
46.00145.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Yueh Pan
CEO | Chief Executive Officer | - | 01/11/01 |
Yuan Chang Cheng
DFI | Director of Finance/CFO | - | 14/14/14 |
Tzu Ming Pan
CTO | Chief Tech/Sci/R&D Officer | - | 07/16/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Lee
CHM | Chairman | 73 | 04/07/04 |
Ching Yi Wang
BRD | Director/Board Member | 83 | 01/20/01 |
Hsu Chih Hsu
BRD | Director/Board Member | - | 07/16/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 113.5 | -0.44% | 187,282 |
| 29/24/29 | 114 | -1.72% | 200,941 |
| 26/24/26 | 116 | -1.28% | 152,153 |
| 25/24/25 | 117.5 | -1.67% | 105,569 |
| 24/24/24 | 119.5 | +1.27% | 41,491 |
End-of-day quote Taipei Exchange, April 30, 2024
More quotes
SunWay Biotech Co Ltd is a Taiwan-based company mainly engaged in the research, development and sale of health foods. The Company's main products are involved in Lactobacillus paracasei subsp. paracasei NTU 101, Monascus purpureus NTU 568 and other related health foods. The Company's main product functions include helping digestion, improving the bacterial ecology of the digestive tract, regulating immunity and allergies. The Company operates products in domestic and overseas markets.
Sector
Food Processing
| 1st Jan change | Capi. | |
|---|---|---|
| -15.61% | 207M | |
| +13.21% | 8.15B | |
| -0.47% | 7.23B | |
| +12.30% | 6.65B | |
| -6.99% | 3.72B | |
| -7.20% | 3.64B | |
| -4.78% | 1.31B | |
| +12.61% | 972M | |
| -43.12% | 863M | |
| -15.02% | 799M |
- Stock Market
- Equities
- 1271 Stock
